RxDoctor Payments DataLook up a doctor →

Anderson Mehrle, MD

Cardiovascular Disease · Bartlesville, OKNPI 1396788022

Payments from drug & device makers

$1,640,677in general payments, 2019–2025

Across 840 payments — averaging $1953.19 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Shockwave Medical, Inc$759K
  • Abbott$316K
  • Novartis$184K
  • Janssen Research & Development, LLC$168K
  • AstraZeneca$43K
  • Vifor (international) Ltd.$38K
  • plus $133K from 32 others

What the payments were for

  • Consulting fees$50,48939%
  • Speaking & faculty fees$45,64935%
  • Travel & lodging$12,52510%
  • Food & beverage$20,52316%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,640,677 in reported general payments places this provider in the 95th percentile of 164 cardiovascular disease providers in Oklahoma.

See all cardiovascular disease providers in Oklahoma

Medicare billing

Part B allowed, 2024
$627,212
Medicare patients
2,370
Services billed
8,692

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban238$237,811
XareltoRivaroxaban228$195,220
EntrestoSacubitril/Valsartan52$56,772
BrilintaTicagrelor69$39,367
JardianceEmpagliflozin33$28,397
FarxigaDapagliflozin Propanediol22$20,619
Repatha SyringeEvolocumab11$7,115
Atorvastatin Calcium388$6,065
ClopidogrelClopidogrel Bisulfate420$5,354
Metoprolol Succinate346$4,541
Ranolazine ErRanolazine55$2,759
Rosuvastatin Calcium87$1,899
Amlodipine Besylate241$1,824
Potassium Chloride115$1,816
Losartan Potassium158$1,603

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$418$237,811238 claims
Johnson & JohnsonXarelto$26,707$195,220228 claims
AstraZenecaBrilinta, Farxiga$42,830$59,98691 claims
NovartisEntresto$183,853$56,77252 claims
Boehringer IngelheimJardiance$16$28,39733 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 164 cardiovascular disease providers in Oklahoma.

Other cardiovascular disease in Bartlesville

See the full list for Oklahoma

Where these figures come from

Is this you, or does something look wrong? →